Samsung Bioepis has welcomed positive six-month Phase III data for its SB17 proposed biosimilar to Stelara, the fourth candidate in the company’s immunology pipeline.
Samsung Bioepis continues to prove itself as one of the busiest developers of biosimilars, divulging in quick succession a collection of data and analysis, including for the firm’s SB17 biosimilar Stelara (ustekinumab) candidate for which it recently out-licensed commercialization rights in global markets to Sandoz.
At the European Academy of Dermatology and Venereology congress currently being held in Berlin, Germany, Samsung presented Phase
As the US biosimilars market moves into its second decade, urgent changes are needed at the FDA if biosimilars are to meet their full potential, according to Biosimilars Forum chief executive Julie Reed.
With a lineup of five high-value biosimilars in the wings, Biocon Biologics may be more selective going forward and plans to take a one product per year approach.
Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.
Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.
